342 related articles for article (PubMed ID: 28296193)
1. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Wang Q; Zheng M; Leil T
CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
4. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
5. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
6. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.
Chang M; Bathena S; Christopher LJ; Shen H; Roy A
Cancer Chemother Pharmacol; 2022 Mar; 89(3):383-392. PubMed ID: 35147740
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
9. Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Chen Y; Zhu R; Ma F; Mao J; Chen EC; Choo EF; Sahasranaman S; Liu L
Biopharm Drug Dispos; 2018 Nov; 39(9):420-430. PubMed ID: 30335192
[TBL] [Abstract][Full Text] [Related]
10. Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes.
Farasyn T; Pahwa S; Xu C; Yue W
Eur J Pharm Sci; 2021 Oct; 165():105951. PubMed ID: 34311070
[TBL] [Abstract][Full Text] [Related]
11. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
13. More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.
Emami Riedmaier A; Burt H; Abduljalil K; Neuhoff S
J Clin Pharmacol; 2016 Jul; 56 Suppl 7(Suppl Suppl 7):S132-42. PubMed ID: 27385171
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
15. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
16. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
Costales C; Lin J; Kimoto E; Yamazaki S; Gosset JR; Rodrigues AD; Lazzaro S; West MA; West M; Varma MVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1018-1031. PubMed ID: 34164937
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.
Varma MV; Lin J; Bi YA; Kimoto E; Rodrigues AD
Drug Metab Dispos; 2015 Jul; 43(7):1108-18. PubMed ID: 25941268
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
Stopfer P; Giessmann T; Hohl K; Sharma A; Ishiguro N; Taub ME; Zimdahl-Gelling H; Gansser D; Wein M; Ebner T; Müller F
Clin Pharmacol Ther; 2016 Sep; 100(3):259-67. PubMed ID: 27256812
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Varma MV; Lai Y; Feng B; Litchfield J; Goosen TC; Bergman A
Pharm Res; 2012 Oct; 29(10):2860-73. PubMed ID: 22638872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]